Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 2Lymphoma 1Leukemia 1Graft vs Host Disease 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × siplizumab × Clear all
NCT00806728 2008-12-11

Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease

MedImmune LLC

Phase 1 Completed
17 enrolled

Graft vs Host Disease, Neoplasms

NCT00105313 2007-06-14

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

MedImmune LLC

Phase 1 Terminated
80 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡